Outcomes with androgen-deprivation therapy plus androgen receptor pathway inhibitors in veterans with de novo metastatic castration-sensitive prostate cancer (mCSPC) who were elderly, frail, or had high comorbidity: a subgroup analysis of enzalutamide and high-volume disease.
